Simplex Trading’s Unity Biotechnology UBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,400
Closed -$2K 9782
2025
Q1
$2K Sell
2,400
-4,500
-65% -$8.13K ﹤0.01% 8090
2024
Q4
$6K Buy
6,900
+300
+5% +$373 ﹤0.01% 7545
2024
Q3
$9K Sell
6,600
-1,300
-16% -$1.91K ﹤0.01% 7287
2024
Q2
$10K Buy
7,900
+100
+1% +$152 ﹤0.01% 7455
2024
Q1
$12K Buy
7,800
+2,900
+59% +$5.03K ﹤0.01% 7503
2023
Q4
$9K Sell
4,900
-21,500
-81% -$40K ﹤0.01% 7538
2023
Q3
$63K Sell
26,400
-11,300
-30% -$29.9K ﹤0.01% 5584
2023
Q2
$96K Sell
37,700
-12,000
-24% -$31.7K ﹤0.01% 5138
2023
Q1
$81K Sell
49,700
-516,600
-91% -$2.07M ﹤0.01% 5405
2022
Q4
$1.55M Buy
566,300
+498,100
+730% +$1.45M ﹤0.01% 2067
2022
Q3
$269K Buy
68,200
+65,100
+2,100% +$411K ﹤0.01% 4223
2022
Q2
$17K Sell
3,100
-1,980
-39% -$16.5K ﹤0.01% 7788
2022
Q1
$56K Sell
5,080
-7,120
-58% -$79.9K ﹤0.01% 6991
2021
Q4
$178K Sell
12,200
-4,950
-29% -$108K ﹤0.01% 5360
2021
Q3
$771K Buy
17,150
+10
+0.1% +$353 ﹤0.01% 3466
2021
Q2
$795K Buy
17,140
+17,104
+47,511% +$824K ﹤0.01% 3468
2021
Q1
$216K Buy
+36
New +$2.46K ﹤0.01% 4628
2020
Q2
Sell
-10
Closed -$59K 8395
2020
Q1
$59K Buy
+10
New +$630 ﹤0.01% 4967
2019
Q4
Hold
0
7006
2019
Q3
Sell
-8
Closed -$76K 7925
2019
Q2
$76K Buy
+8
New +$681 ﹤0.01% 4467

Simplex Trading's UBX Position: Q4 2025 in Review

Simplex Trading sold out of Unity Biotechnology (UBX) in Q4 2025, closing a stake of 2,571 shares.

Simplex Trading first reported a position in UBX in Q1 2019 and held it in 15 quarters. The position peaked at $133K in Q4 2021. 0 funds tracked by Wall St. Rank hold UBX as of Q4 2025.

  • Simplex Trading reported no remaining Unity Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 2,571 Unity Biotechnology shares in Q4 2025.
  • Simplex Trading first reported a position in Unity Biotechnology in Q1 2019 and held it in 15 quarters.
  • Simplex Trading's Unity Biotechnology position peaked at $133K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.